Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933203 · ClinicalTrials.gov registry record
Genetic Biomarkers of Executive Stress
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 51
- Enrollment target
NCT02933203: Completed study, sponsored by Stanford University.
NCT02933203 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02933203 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to examine whether stress predicts telomere length in individuals who hold executive-level positions. Telomeres are the caps at the end of each strand of DNA that may affect how cells age. Subjects will complete an online survey/interview and provide one blood sample or saliva samples. The goal is to understand whether stress predicts genetic markers of longevity.
Primary Outcome
Subjects will come in for 1 visit to give a saliva or blood sample which will be used to measure telomere length.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-06 |
What the finished NCT02933203 record still lists
NCT02933203 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 51 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02933203 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02933203 about?
NCT02933203 is a clinical study titled "Genetic Biomarkers of Executive Stress". The purpose of this study is to examine whether stress predicts telomere length in individuals who hold executive-level positions. Telomeres are the caps at the end of each strand of DNA that may affect how cells age. Subjects will complete an online survey/interview and provide one blood sample or ...
What is the current status of trial NCT02933203?
This trial is currently completed. The enrollment target is 51 participants. The study started on 2015-10. Estimated completion is 2017-06.
Who is sponsoring clinical trial NCT02933203?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia